Diagnostic Potential of CD34+ Cell Antigen Expression in Myelodysplastic Syndromes

Smet, Dieter De; Trullemans, Fabienne; Jochmans, Kristin; Renmans, Wim; Smet, Lut; Heylen, Olivier; Bael, Anne-Mie; Schots, Rik; Leus, Barbara; Waele, Marc De

doi:10.1309/ajcpagvo27rptotv

Cited by 16 publications

(20 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, we tested the myeloblastic cell population as another source of circulating miRNAs in MDS. We previously measured miRNA expression profiles in CD34+ MDS cells [10] (the majority of MDS myeloblasts are CD34+ [18]) and here we used these data to assess the correlation between cellular and plasma miRNA levels. However, the levels of plasma miRNAs did not reflect their levels in CD34+ cells.…”

Section: Discussionmentioning

confidence: 99%

Microarray profiling defines circulating microRNAs associated with myelodysplastic syndromes

Merkerová¹,

Hruštincová²,

Krejčík³

et al. 2017

neo

View full text Add to dashboard Cite

Circulating microRNAs (miRNAs) are non-coding RNAs secreted into body fluids, and aberrant levels of these miRNAs correlate with diseases of various origins, making them highly potential clinical biomarkers. We investigated the spectrum of circulating miRNAs in the plasma of myelodysplastic syndrome (MDS) patients to identify miRNAs showing discriminatory levels in the patients with different prognosis. Plasma samples were analyzed with microarrays to define miRNA profiles, and the deregulated miRNAs were further studied using droplet digital PCR. With regard to the prognosis, the levels of miR-27a-3p, miR-150-5p, miR-199a-5p, miR-223-3p and miR-451a were reduced in higher-risk MDS. Multivariate analysis indicated miR-451a level as an independent predictor of progression-free survival (HR = 0.072, P = 0.006) and revealed a significant association of miR-223-3p level with overall survival (HR = 0.039, P = .032). Our data demonstrate that plasma levels of specific miRNAs are associated with MDS patient outcome and may add information beyond the currently used scoring systems.

show abstract

Section: Discussionmentioning

confidence: 99%

Microarray profiling defines circulating microRNAs associated with myelodysplastic syndromes

Merkerová¹,

Hruštincová²,

Krejčík³

et al. 2017

neo

View full text Add to dashboard Cite

show abstract

“…Several parameters for evaluation of blasts have been proposed, including expression of nonlineage markers CD7, CD2, CD5, and CD56; variation in levels of immaturity markers CD34, CD117, and CD38; and variation of levels of myeloid markers CD13, CD33, CD15, and CD11b. Although the sensitivity and specificity of individual markers are generally low (best seen as a loss of CD38, bright CD117, and CD123 expression), 15,16 combining multiple markers into a scoring system improves FCIP performance, with sensitivity ranging between 44% and 98%, and specificity between 78% and 100%. 17 There are two approaches in FCIP for myeloid neoplasms (as well as in other FCIP applications): ones that define abnormalities quantitatively using mean fluorescence intensity of individual antigens, 7,8,15,16,18,19 and ones that define abnormalities qualitatively, looking at the pattern of expression.…”

Section: Discussionmentioning

confidence: 99%

“…Although the sensitivity and specificity of individual markers are generally low (best seen as a loss of CD38, bright CD117, and CD123 expression), 15,16 combining multiple markers into a scoring system improves FCIP performance, with sensitivity ranging between 44% and 98%, and specificity between 78% and 100%. 17 There are two approaches in FCIP for myeloid neoplasms (as well as in other FCIP applications): ones that define abnormalities quantitatively using mean fluorescence intensity of individual antigens, 7,8,15,16,18,19 and ones that define abnormalities qualitatively, looking at the pattern of expression. 4,6,10,[20][21][22][23][24][25] These two approaches differ in test performance characteristics and validation requirements.…”

Section: Discussionmentioning

confidence: 99%

Loss of Blast Heterogeneity in Myelodysplastic Syndrome and Other Chronic Myeloid Neoplasms

Jevremović

Timm

Reichard

et al. 2014

American Journal of Clinical Pathology

View full text Add to dashboard Cite

Objectives: Flow cytometry immunophenotyping has been suggested as an adjunctive technique in the evaluationUpon completion of this activity you will be able to:• discuss the role of flow cytometry immunophenotyping in the diagnosis of chronic myeloid neoplasms.• recognize normal and dysplastic patterns of CD13/HLA-DR expression on CD34-positive blasts.The ASCP is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The ASCP designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit ™ per article. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity qualifies as an American Board of Pathology Maintenance of Certification Part II Self-Assessment Module.The authors of this article and the planning committee members and staff have no relevant financial relationships with commercial interests to disclose.

show abstract

“…-cells, however, normal hematopoietic stem cells could not detect the expression of CD96 [9]. In an animal experiment, Wilke divided CD34+CD38-cells into two groups: CD34 +…”

Section: Cd38mentioning

confidence: 99%

Expression and Significance of CD123 and CD96 in Myelodysplastic Syndrome

Zhang¹,

Jiang²,

Zhang³

et al. 2016

Advances in Computer Science Research

View full text Add to dashboard Cite

Abstract. Objective: To explore the relationship between the expression of CD123 and CD96 and prognosis in MDS. Methods: 89 MDS patients and 20 controls are enrolled. The patients are grouped by the risk. All participants are detected by bone marrow biopsy. Mononuclear cells are extracted, CD34+CD38-CD123+ and CD34+CD38-CD96+ cells are counted by flow cytometry. Expression of the two types of cells in control group, observation group and its subgroups are analyzed. Results: MDS patients display significantly larger proportion of CD34+ cells and CD34+CD38-cells than that of controls (P<0.05) and the proportion increases with the risk. In the low-and middle-risk group, the rates of complete remission (CR ) and partial remission (RR) are significantly higher in CD123-CD96-cells than that in CD123+CD96+ cells. In the middle-and high-risk patients group, RR is significantly higher in CD123-cells than that in CD123+ cells (P<0.05) and CR is significantly higher in CD96-cells than that in CD96+ cells (P<0.05). Conclusion: The differentiation of CD34+ cells in bone marrow of MDS patients is abnormal, with the high expression of CD123 and CD96 cells. These findings might partly explain the cause of MDS patients with hematopoietic stem cells malignant clone.

show abstract

Diagnostic Potential of CD34+ Cell Antigen Expression in Myelodysplastic Syndromes

Cited by 16 publications

References 26 publications

Microarray profiling defines circulating microRNAs associated with myelodysplastic syndromes

Microarray profiling defines circulating microRNAs associated with myelodysplastic syndromes

Loss of Blast Heterogeneity in Myelodysplastic Syndrome and Other Chronic Myeloid Neoplasms

Expression and Significance of CD123 and CD96 in Myelodysplastic Syndrome

Contact Info

Product

Resources

About